Observational studyThe Prostate2026
[
Observational study in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare choline PET-CT and PSMA PET-CT in a cohort of patients with high-risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results.
methodsAn observational study was conducted in 116 patients with high-risk prostate cancer between January 2021 and January 2024. All patients underwent sequential choline and PSMA PET-CT scans. Clinical and pathological data were collected, and extraprostatic disease and SUVmax values in these locations were evaluated.
resultsThe mean age was 68.9 years (SD 7.8) and the median PSA at diagnosis was 14.6 ng/mL. The most frequent ISUP grade was 2 (28.5%). The mean interval between the two tests was 19 days. All patients had detectable intraprostatic tumor activity with both techniques. In 28.6% of patients with negative choline PET-CT, PSMA PET-CT detected extraprostatic disease. In the subgroup undergoing radical prostatectomy, PSMA PET-CT positivity was significantly associated with the presence of positive surgical margins (p < 0.05). PSMA PET-CT showed a significant association with ISUP ≥ 3 (OR 2.42; p < 0.05). SUVmax in extraprostatic lesions was higher in patients with ISUP ≥ 3 in both choline and PSMA PET-CT, being stronger with PSMA PET-CT (OR 22.67 vs. 3.26).
conclusionPSMA PET-CT offers superior diagnostic performance to choline PET-CT in patients with high-risk prostate cancer which has a clinical impact on therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.